“We believe a national RSV program is needed so all infants born in Australia have access to Beyfortus. A national program for next year’s RSV season will make it easier for parents and healthcare professionals to discuss infant eligibility, no matter where the child is born," said Regis Launay, the general manager of vaccines for Sanofi Australia and New Zealand. …
More states announce RSV programs as families call for national action
March 26, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News -
Commercial outsourcing emerges as a strategic option to patient access
July 1, 2026 - - Latest News -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News